肿瘤细胞治疗研究
英文原题：Acute lymphoblastic leukemia relapse: biomarkers, hopes, and challenges.
急性淋巴细胞白血病（ALL）在成人中是一种罕见疾病，但却是最常见的儿童恶性肿瘤，也是全球癌症患儿死亡的首要原因。
急性淋巴细胞白血病（ALL）在成人中较罕见，但它是最常见的儿童恶性肿瘤，也是全球癌症患儿死亡的首要原因。虽然初始治疗方案可使大多数患者缓解，许多病例仍会在治疗期间或治疗后复发。复发难以治疗，仍是ALL相关死亡的主要原因之一。因此，阐明ALL复发的生物学机制、确定可靠的生物标志物以更准确预测复发风险，以及发现可药物靶向的新靶点以制定基于风险特征的精准治疗，至关重要。本文综述ALL研究的最新进展，重点介绍复发机制，并讨论相关希望与挑战。
Acute lymphoblastic leukemia (ALL) is a rare disease in adults, but is the most common pediatric malignancy and the leading cause of death among children with cancer worldwide. While initial treatment regimens induce remission in most patients, relapses still occur in many cases during or after treatment. Relapses are difficult to treat and continue to be one of the leading causes of ALL-related deaths. Thus, it is essential to understand the biological mechanisms underlying ALL relapses, and to identify reliable biomarkers for better relapse risk prediction and novel druggable targets for precision treatments tailored to risk profiles. Here we review the latest developments in ALL research with a focus on relapse mechanisms, and we discuss related hopes and challenges.
MEMBER ACCOUNT
登录成功会直接打开下一页。
